Sarcoma, Soft Tissue Clinical Trial
Official title:
Phase II Evaluation of Ifosfamide Plus Doxorubicin & Filgrastim Versus Gemcitabine Plus Docetaxel & Filgrastim in the Treatment of Localized Poor Prognosis Soft Tissue Sarcoma
The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.
The purpose of this study is to explore the relative activity and toxicity of a newer
combination of chemotherapy drugs, gemcitabine and docetaxel, as compared to a standard
combination of chemotherapy drugs, ifosfamide and doxorubicin.
Ifosfamide and Doxorubicin, given in combination, are recognized as a standard of care for
some types of sarcoma. Both gemcitabine and docetaxel are approved by the US Food and Drug
Administration (FDA) for the treatment of some cancers (cancers of the pancreas, lung)
because patients with those cancers treated with either gemcitabine or docetaxel experienced
shrinkage of their tumor or improvement in their symptoms. However, neither gemcitabine or
docetaxel is approved for sarcoma, but the combination of gemcitabine and docetaxel is a
standard treatment for advanced sarcoma.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03985722 -
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
|
Phase 1 | |
| Withdrawn |
NCT02464332 -
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
|
Phase 1 | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00289809 -
TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01185964 -
A Study of IMC-3G3 in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00753688 -
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
|
Phase 3 | |
| Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
| Completed |
NCT03798795 -
Radiomics for Tumor Grading of Soft Tissue Sarcomas.
|
||
| Terminated |
NCT02929394 -
Trabectedin Maintenance Post 1st-line in STS
|
Phase 3 | |
| Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00406601 -
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
|
Phase 2 | |
| Completed |
NCT00297258 -
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT06114173 -
Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
|
Early Phase 1 | |
| Completed |
NCT00061659 -
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT03815474 -
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
|
Phase 2 | |
| Recruiting |
NCT02812654 -
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
|
Phase 2 | |
| Completed |
NCT00204620 -
Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
|
Phase 2 | |
| Completed |
NCT03058406 -
A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
|
||
| Active, not recruiting |
NCT02415816 -
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
|
N/A |